Hjem › T-celle-lymfom › Wisconsin
Kliniske studier for T-celle-lymfom i Wisconsin
5 studier for T-celle-lymfom søker deltakere på steder i Wisconsin.
Byer i Wisconsin
Offisiell studietekst (engelsk)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Marshfield Medical Center-EC Cancer Center, Eau Claire
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- og 5 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04803201Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Wisconsin, Milwaukee
RekruttererObservasjonsstudie
Alder 0 til 38 · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06131801Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- University of Wisconsin Carbone Cancer Center, Madison
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06561048Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Marshfield Medical Center-Marshfield, Marshfield
- og 9 flere
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 14. sep. 2026 · NCT06724237Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital of Wisconsin, Milwaukee
RekruttererFase 1
Alder 1 til 21 · Alle kjønn · Oppdatert 6. des. 2024 · NCT05476770Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.